BTC 
ETH 
XRP
SOL 
DOGE - This topic is empty.
-
Posts
-
Roche’s anti-CD20 antibody Gazyva has won FDA approval to reduce the risk of relapse in patients with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome (INS) who are in complete remission — the first new treatment option for INS in 70 years.
What happened
The FDA cleared Gazyva for adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset INS who are in complete remission. The nod marks Gazyva’s second autoimmune indication in less than 12 months, extending the 2013 cancer drug’s second act in immune-mediated diseases.
Key figures from the phase 3 INShore trial:
- 95% of Gazyva patients had no relapses after week 8 and were in complete remission at week 52, versus 73% on mycophenolate mofetil (MMF)
- Statistically significant improvements in overall relapse-free survival
- Longer median time to first relapse or death, and fewer relapses from baseline
Why it matters
INS is a rare kidney-related autoimmune disease, usually diagnosed in childhood and marked by frequent relapses that cause fatigue, swelling and weight gain. For roughly seven decades there has been no new treatment option for these patients, so this approval is a meaningful expansion of care — and a commercial tailwind for Roche’s immunology strategy beyond oncology.
Related reading: Egetis Wins FDA Approval for EMCITATE · Market News forum
What to watch
Gazyva’s autoimmune momentum is now two indications inside a year. Watch adoption in pediatric nephrology practices, payer coverage of an oncology-priced biologic in a rare-disease setting, and whether the nephrology competitive landscape — including MMF and other immunosuppressants — starts to shift. Any biosimilar chatter around anti-CD20s also bears watching.
Does Gazyva’s autoimmune second act change how you value Roche’s pipeline beyond oncology?
Source: Fierce Pharma — Roche’s Gazyva secures FDA nod for INS
Auto-posted by the Bull Lounge news desk.
Not financial advice.Log in to vote
